Jiangsu Caina Medical made Monoject sterile syringes for Cardinal Health but did not properly investigate pump-incompatibility complaints, leading to a Class I recall.
What happened
FDA inspected the firm's facility in Jiangyin City, Jiangsu, China, from March 11 through March 23, 2024. Investigators found that starting in July 2023 the firm received at least 41 US complaints that its sterile syringes were not recognized by, or did not work with, syringe pumps, and that the firm closed the complaints without opening a corrective action (CAPA). FDA also found the firm's risk analysis for the syringes did not include the hazard of pump use, and that it did not submit required reports for malfunctions that may have caused serious injury or death.
What FDA found
The firm did not analyze complaint data to spot causes of nonconforming product or other quality problems.
21 CFR 820.100(a)(1)The firm did not investigate the cause of nonconformities, including complaints of pump incompatibility and inaccurate dosing.
21 CFR 820.100(a)(2)The firm's risk analysis for the syringes did not include the hazard of use in an infusion pump, and the risk controls it listed were not verified as implemented or effective.
21 CFR 820.30(g)The firm did not submit reports to FDA within 30 calendar days for device malfunctions that could contribute to death or serious injury.
21 CFR 803.50(a)(2)
What FDA wants
FDA asks the firm to reply in writing within fifteen business days describing the specific steps taken to fix the violations, how it will prevent recurrence, and a timetable for any actions not yet complete. FDA also says the firm's syringes are subject to detention without physical examination at the US border until the violations are addressed.
Who should pay attention
- brands and distributors that buy private-label syringes from contract manufacturers
- hospital staff and clinicians who select syringes for infusion and enteral pumps
- quality teams that handle complaints, CAPA and FDA malfunction reporting
This is a summary. Read the original letter on fda.gov.